Radiopharmaceuticals Market (2026 - 2040)

Radiopharmaceuticals Market Summary

The global radiopharmaceuticals market size was valued at USD 10.3 billion in 2025 and is projected to grow from USD 11.0 billion in 2026 to USD 33.4 billion by 2040, at a CAGR of 8.2% from 2026 to 2040. North America dominated the market, accounting for the revenue share of 51.2% in 2025. The market is expanding as nuclear medicine gains wider use in diagnostic imaging and targeted radionuclide therapy. 

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

PET and SPECT radiopharmaceuticals remain important for molecular imaging, with oncology accounting for a major share of clinical use, while therapeutic products are gaining use in prostate cancer, neuroendocrine tumors, thyroid disorders, and bone metastases. Demand for PET tracers is supported by the growing use of PET/CT for cancer detection, staging, treatment planning, and disease monitoring. Therapeutic radiopharmaceuticals based on lutetium-177 are also gaining clinical use, supported by the broader availability of targeted cancer treatments. At the same time, the market faces supply constraints for short-lived and emerging radioisotopes, including actinium-225, along with the need for specialized production facilities, trained personnel, radiation-safe handling, and time-sensitive transportation.

To learn more about this report, Download Free Sample Report

Expansion of isotope production capacity, radiopharmacy infrastructure, and targeted radiopharmaceutical pipelines is therefore shaping market development. Overall, the market is driven by clinical demand for molecular imaging and targeted cancer therapy, with supply infrastructure remaining a key factor.

Market Dynamics

Market Concentration & Characteristics

The degree of innovation in the market is high, supported by new molecular targets, radionuclides, radioligand therapies, and imaging agents. Product development is moving beyond established tracers such as F-18 FDG toward targeted agents for specific receptors and proteins. In therapeutic applications, Lu-177 remains an important radionuclide, while Ac-225 is receiving increased development activity for targeted alpha therapy. Theranostic products connect diagnostic imaging with targeted treatment, as seen with PSMA imaging and Lu-177 therapy in prostate cancer. Innovation also extends to isotope production, radiolabeling, manufacturing, dosimetry, and radiopharmacy operations because radioactive products require specialized handling and timely delivery. FDA approvals and expanded indications for radiopharmaceutical therapies are adding clinical applications. This combination of product and production innovation supports development across both diagnostic and therapeutic segments.

Barriers to market entry are high in the radiopharmaceutical industry because companies require specialized production facilities, radioactive material licenses, trained personnel, quality systems, and reliable isotope supply. Short radioactive half-lives also require suitable production locations and time-sensitive distribution networks. Access to isotopes such as Lu-177 and Ac-225 can affect the ability of new companies to scale products. Established companies with manufacturing sites, isotope agreements, radiopharmacy networks, and hospital relationships have operational advantages. Reliable logistics and radiopharmacy capacity are also important because many products require rapid movement from production sites to clinical facilities. Companies entering the market, therefore, need access to qualified suppliers and suitable treatment networks. These requirements increase capital needs and development time for new entrants. Smaller companies often enter the market through focused product development, partnerships, contract manufacturing, or isotope supply agreements rather than by building a complete infrastructure.

To learn more about this report, Download Free Sample Report

The impact of regulations on the global market is significant because products are subject to pharmaceutical requirements and radiation safety controls. Companies must comply with requirements covering product quality, manufacturing, radioactive material handling, transportation, storage, and clinical use. Regulatory review is required for new diagnostic and therapeutic radiopharmaceuticals before commercial use. The short half-life of many radiopharmaceuticals imposes operational requirements, as production, release testing, transportation, and administration require close coordination. These controls affect facility design, production procedures, logistics, documentation, and product approval timelines. Regulatory requirements also cover radioactive material licenses, facility controls, product documentation, and safe handling. These requirements increase compliance work for companies operating across multiple countries and product categories. The regulatory environment, therefore, directly affects market entry, manufacturing expansion, product launches, and radiopharmaceutical supply across healthcare facilities.

Product substitutes in the market are low to moderate because radiopharmaceuticals provide functions that are not fully replaced by other medical products. PET and SPECT radiopharmaceuticals provide functional and molecular information that complements anatomical imaging methods such as CT and MRI. In therapy, targeted radiopharmaceuticals deliver radiation to selected cells based on molecular targets, while chemotherapy, external beam radiation, surgery, and other systemic treatments can serve as alternatives for some cancer indications. Established diagnostic tracers have alternative imaging methods in some clinical situations, while targeted radiopharmaceutical therapies have fewer direct substitutes for specific molecular targets. In oncology, external beam radiation and systemic medicines can compete with radiopharmaceutical therapies depending on the cancer type, treatment stage, and molecular target. Therefore, clinical evidence and treatment availability affect substitution levels.

Geographical expansion in the radiopharmaceutical industry is moderate to high, as companies are expanding access through regional manufacturing, radiopharmacy networks, isotope supply agreements, and treatment-center expansion. Geographic reach is shaped by radioactive half-life, transport requirements, regulatory requirements, and local production capacity. Short-lived PET radiopharmaceuticals often require production near imaging centers, thereby supporting regional manufacturing and distribution networks. Companies are expanding production infrastructure and partnerships to improve access across healthcare markets. Differences in reimbursement, regulatory requirements, nuclear medicine infrastructure, and isotope availability also affect regional access. These factors support gradual geographic expansion, with established markets generally having broader radiopharmacy and treatment infrastructure. Expansion is also supported by demand for PET imaging in countries developing nuclear medicine capacity. Local isotope production and radiopharmacy services remain important for access in new regions.

Analyst Perspective

The radiopharmaceutical market is supported by the increasing use of molecular imaging, the growth of targeted radionuclide therapy, and the wider clinical use of theranostics. Oncology continues to account for a large portion of demand, while cardiology and neurology support diagnostic applications. Market development is closely linked to isotope availability, production capacity, radiopharmacy networks, specialized logistics, and treatment infrastructure. The expansion of PET and SPECT facilities and the development of new radionuclide therapies are driving demand across diagnostic and therapeutic applications in established and emerging markets.

Product Insights

The SPECT radiopharmaceuticals sub-segment led the market with the largest revenue share of 74.5% in 2025, supported by the established use of Tc-99m-based imaging, broad availability of SPECT systems, recurring nuclear medicine procedures, established radiopharmacy networks, and use in cardiac, bone, renal, thyroid, and lung imaging. SPECT also benefits from established clinical workflows across hospitals and diagnostic centers, supporting regular tracer utilization. Tc-99m-based products remain widely used for routine nuclear medicine procedures, while SPECT infrastructure is available across a broad range of healthcare facilities. These factors support consistent demand for SPECT radiopharmaceuticals across established markets.

The PET radiopharmaceuticals sub-segment is projected to grow at the fastest CAGR of 9.0% during the forecast period, supported by increasing use of molecular imaging, rising oncology PET procedures, wider use of targeted tracers, expansion of neurological and cardiac PET applications, and integration of PET imaging with theranostic treatment processes. PET provides molecular information that supports cancer staging, treatment selection, and disease monitoring. Development of tracers for specific molecular targets is also expanding clinical applications. For instance, in September 2026, Telix Pharmaceuticals received U.S. FDA approval for Pixclara (floretyrosine F 18), a PET imaging drug for brain tumor imaging in adults and pediatric patients with suspected or known glioma.

Application Insights

The oncology imaging sub-segment led the market with the largest revenue share of 38.1% in 2025, supported by high cancer incidence, increasing PET and SPECT use for tumor detection and staging, wider adoption of molecular imaging, use of targeted tracers for specific tumor markers, growing demand for treatment planning, and the use of imaging for disease monitoring. Oncology remains a broad application area for F-18 FDG, PSMA-targeted tracers, somatostatin receptor imaging, and other cancer-focused radiopharmaceuticals. Greater use of molecular imaging in targeted oncology treatment also links diagnostic procedures with therapeutic radiopharmaceutical use. For instance, in October 2025, Lantheus announced that the FDA had established a PDUFA date for LNTH-2501 (Ga-68 edotreotide), a PET diagnostic imaging kit for the localization of somatostatin receptor-positive neuroendocrine tumors.

The neurology imaging sub-segment is expected to grow at the fastest CAGR of 9.2% during the forecast period, supported by increasing use of PET for Alzheimer’s disease assessment, growing demand for amyloid imaging, development of tau-targeted tracers, wider use of molecular biomarkers, and increasing integration of imaging into neurological disease assessment. PET provides information on brain pathology that supports the evaluation of cognitive impairment and selection of patients for certain targeted treatments. Development of additional brain imaging agents is also expanding the use of radiopharmaceuticals across neurological conditions. For instance, in July 2025, Lantheus completed its acquisition of Life Molecular Imaging, adding Neuraceq, an F-18 PET radiodiagnostic for beta-amyloid imaging in Alzheimer’s disease, to its portfolio.

End Use Insights

The hospitals segment led the market with the largest revenue share of 49.8% in 2025, supported by high patient volumes, established nuclear medicine departments, access to PET and SPECT imaging systems, availability of trained specialists, administration of therapeutic radiopharmaceuticals, and integration of imaging with oncology treatment. Hospitals also manage radiopharmaceutical procurement, patient preparation, imaging, therapy administration, radiation safety, and patient monitoring. Their ability to provide multiple diagnostic and therapeutic services within a single facility supports the recurring demand for radiopharmaceuticals. For instance, in December 2025, the University of Rochester Medical Center and GE HealthCare entered into a seven-year collaboration to expand PET/CT and SPECT/CT capabilities and add in-house production of diagnostic radiopharmaceutical tracers for molecular imaging, precision medicine, and theranostics across the health system. This development directly supports the role of hospitals as major users and providers of radiopharmaceutical-based services.

To learn more about this report, Download Free Sample Report

The specialty clinics & cath labs segment is anticipated to grow at the fastest CAGR of 10.7% during the forecast period, supported by increasing use of nuclear cardiology procedures, growth in cardiac disease diagnosis, wider availability of PET and SPECT imaging, expansion of specialty oncology services, and greater use of targeted radiopharmaceuticals in disease-specific care. Cath labs use nuclear medicine alongside other cardiac diagnostic procedures to assess myocardial perfusion and cardiac function, creating demand for radiopharmaceuticals such as Tc-99m and Rb-82-based products. Specialty clinics also support the use of molecular imaging for selected oncology applications, including targeted imaging of specific tumor markers. Increasing patient referrals to specialized centers for cardiac and oncology assessment is supporting procedure volumes. Expansion of imaging equipment, radiopharmacy services, trained personnel, and specialized treatment infrastructure further supports radiopharmaceutical use across these facilities.

Regional Insights

The North America radiopharmaceutical market held the largest revenue share of 51.2% in 2025, supported by established PET and SPECT infrastructure, high oncology imaging volumes, and broad use of targeted radiopharmaceuticals. The region has a large installed base of PET/CT systems and specialized nuclear medicine centers, which support steady demand for diagnostic tracers. Therapeutic radiopharmaceutical use is increasing with the wider adoption of Lu-177-based treatments and theranostic procedures. A strong network of radiopharmacies, isotope suppliers, manufacturers, and specialized logistics providers supports product availability across major healthcare centers. Clinical research activity is also expanding the use of targeted PET tracers and therapeutic radionuclides. These factors maintain North America's leading position in the global market.

To learn more about this report, Download Free Sample Report

U.S. Radiopharmaceuticals Market Trends

The radiopharmaceutical market in the U.S. accounted for the largest market revenue share in North America in 2025, supported by high PET utilization, advanced nuclear medicine infrastructure, and a large oncology patient base. Demand for F-18 FDG remains supported by established oncology imaging procedures, while PSMA-targeted PET is expanding the use of molecular imaging for prostate cancer. Therapeutic radiopharmaceutical use is also increasing, driven by Lu-177-based treatments and the development of alpha-emitting products. Commercial radiopharmacy networks support production and distribution across multiple healthcare facilities, which is important for short-lived products. The U.S. also has strong clinical development activity for new diagnostic tracers and targeted therapies. These factors support continued demand across PET, SPECT, beta-emitting, and alpha-emitting radiopharmaceuticals.

Europe Radiopharmaceuticals Market Trends

The radiopharmaceutical market in Europe is supported by extensive nuclear medicine infrastructure, PET and SPECT utilization, and increasing use of theranostic products. Oncology remains a key application, while cardiology and neurology provide additional demand for diagnostic radiopharmaceuticals. The region has active research and manufacturing capabilities for Lu-177, Ga-68, F-18, and other radionuclides used in clinical practice. Germany, France, and the UK account for a substantial portion of regional demand through their nuclear medicine networks and specialist treatment centers. The expansion of targeted radiopharmaceutical therapies is increasing the requirements for isotope supply, radiopharmacy capacity, and treatment facilities. Supply continuity remains an important business factor due to reactor availability, isotope production capacity, and time-sensitive distribution requirements.

The UK radiopharmaceutical market is supported by established nuclear medicine services, PET imaging capacity, and research activity in oncology and molecular imaging. Demand for PET tracers is supported by cancer diagnosis, staging, treatment planning, and monitoring procedures across specialist centers. The country also has active clinical research in radioligand therapy and targeted radionuclide treatment. Radiopharmacy infrastructure supports the preparation and distribution of short-lived diagnostic products across healthcare facilities. Research centers and specialist hospitals are also involved in the development and evaluation of new radiopharmaceutical products. Continued use of PET imaging and development of targeted therapies are therefore supporting demand for diagnostic and therapeutic radiopharmaceuticals in the UK.

The radiopharmaceutical market in Germany represents an important European market due to its large network of nuclear medicine departments, PET facilities, cyclotrons, and research centers. Oncology imaging supports demand for F-18 FDG and targeted PET tracers, while cardiology and neurology provide additional diagnostic applications. The country also has established clinical use of therapeutic radiopharmaceuticals, including Lu-177-based treatments. Research institutions support the development of new tracers, radionuclides, and theranostic treatment processes. Germany's radiopharmaceutical industry also includes manufacturers and specialized suppliers involved in production, radiolabeling, and distribution. These factors support demand across diagnostic and therapeutic products and maintain Germany's role as a key European market.

The France radiopharmaceutical market is driven by PET and SPECT imaging, nuclear medicine departments, and oncology treatment facilities. Demand for diagnostic products is supported by the use of F-18 FDG and targeted tracers across cancer imaging and other clinical applications. Therapeutic radiopharmaceutical use is also expanding as hospitals adopt targeted radionuclide treatments for selected cancers. France has established radiopharmacy capabilities that support the preparation and distribution of radioactive products for clinical use. Research activity in nuclear medicine is contributing to the development of new tracers and treatment applications. Growth in molecular imaging and targeted oncology therapies is therefore supporting demand for radiopharmaceutical products across French healthcare facilities.

Asia-Pacific Radiopharmaceuticals Market Trends

The radiopharmaceutical market in the Asia Pacific is anticipated to grow at the fastest CAGR of 10.6% during the forecast period, supported by the expansion of PET and SPECT infrastructure, the increasing cancer burden, the growing use of molecular imaging, and the development of local isotope production capacity. Japan, China, India, South Korea, and Australia are expanding nuclear medicine capacity through new imaging centers, cyclotrons, radiopharmacies, and treatment facilities. Demand is also increasing for targeted PET tracers and therapeutic radionuclides used in oncology. Local production is gaining importance as healthcare systems seek more reliable access to short-lived isotopes and therapeutic radionuclides. Growing clinical research activity is also expanding the use of radiopharmaceuticals across oncology, cardiology, and neurology. These factors support faster market development in the Asia Pacific than in established regions.

The Japan radiopharmaceutical market has a mature nuclear medicine market supported by established PET and SPECT infrastructure, trained specialists, and regular use of diagnostic radiopharmaceuticals. Oncology imaging remains an important driver of demand, while cardiac and neurological applications also contribute to diagnostic tracer use. The country also has established research and manufacturing capabilities for medical radioisotopes and radiopharmaceutical products. The development of targeted imaging agents is supporting broader use of molecular imaging in cancer care. Japan's aging population is increasing the need for diagnostic procedures across chronic and age-related diseases, supporting nuclear medicine utilization. The expansion of theranostic research and targeted radiopharmaceutical development is increasing demand for both diagnostic tracers and therapeutic products.

The radiopharmaceutical market in China is a key growth market in the Asia Pacific, supported by the expansion of PET/CT and SPECT/CT infrastructure and rising demand for oncology imaging. Increasing volumes of cancer diagnoses are supporting the use of F-18 FDG and other PET radiopharmaceuticals across major hospitals. The country is also developing domestic production capacity for therapeutic radionuclides, including Lu-177, supporting the expansion of targeted radionuclide therapy. Greater availability of local isotope supply can reduce dependence on international sources and support treatment scheduling. Research institutions and pharmaceutical companies are developing radiopharmaceutical products for additional molecular targets and cancer indications. These factors are increasing demand for diagnostic and therapeutic radiopharmaceuticals across China's growing nuclear medicine network.

Latin America Radiopharmaceuticals Market Trends

The radiopharmaceutical market in Latin America is anticipated to grow at a significant CAGR during the forecast period, supported by increasing PET imaging capacity, growing oncology demand, and the expansion of nuclear medicine services in major urban healthcare centers. Brazil represents the largest market in the region, supported by an established nuclear medicine infrastructure and a growing network of PET facilities. Other countries are gradually increasing access to PET and SPECT services through new imaging centers and radiopharmacy capacity. Limited infrastructure for isotope production and distribution remains a constraint in several countries, particularly for short-lived products. Growth in cancer diagnosis and demand for molecular imaging are increasing the need for diagnostic radiopharmaceuticals. Expansion of therapeutic radiopharmaceutical services is also creating additional demand for Lu-177 and other radionuclides.

The Brazil radiopharmaceutical market is driven by its large healthcare system, established nuclear medicine centers, and increasing use of PET imaging. Oncology is a major source of diagnostic radiopharmaceutical demand, with F-18 FDG widely used for cancer imaging. Expansion of PET/CT capacity in major cities is increasing access to molecular imaging services. Brazil also has domestic nuclear medicine and isotope production capabilities that support the supply of selected radiopharmaceuticals. Demand for therapeutic products is increasing as specialized oncology centers expand radionuclide treatment services. These factors support the steady development of both diagnostic and therapeutic radiopharmaceutical applications across the Brazilian healthcare market.

Middle East & Africa Radiopharmaceuticals Market Trends

The radiopharmaceutical market in the Middle East & Africa is developing through the expansion of PET imaging, nuclear medicine departments, and oncology treatment facilities in major healthcare centers. Gulf countries account for an increasing share of regional demand due to expanding access to advanced cancer diagnostics and radionuclide therapy. Saudi Arabia and the UAE are expanding PET imaging and targeted treatment capabilities, creating demand for diagnostic tracers and therapeutic radiopharmaceuticals. South Africa also contributes through established nuclear medicine services and isotope-related capabilities. The region continues to face supply and distribution challenges for short-lived radionuclides due to limited local production in several countries. The expansion of specialist treatment centers and radiopharmacy services is supporting the wider use of radiopharmaceuticals across the region.

The Saudi Arabia radiopharmaceutical market is supported by the expansion of oncology centers, PET imaging capacity, and nuclear medicine treatment services. Increasing volumes of cancer diagnoses are supporting demand for PET radiopharmaceuticals used in disease detection, staging, and treatment monitoring. Major medical centers are also expanding targeted radionuclide therapy capabilities, creating demand for therapeutic products such as Lu-177-based radiopharmaceuticals. The development of specialized nuclear medicine departments is increasing the requirements for radiopharmacy services, radiation handling, and trained personnel. Demand is concentrated around major healthcare centers where PET and radionuclide therapy infrastructure are available. Continued development of advanced oncology services is therefore supporting wider use of diagnostic and therapeutic radiopharmaceuticals in Saudi Arabia.

Key Radiopharmaceutical Company Insights

The radiopharmaceutical industry is witnessing competition across diagnostic imaging, therapeutic radiopharmaceuticals, and isotope-related services, supported by increasing use of PET and SPECT imaging and targeted radionuclide therapy. Lantheus, Curium, GE HealthCare, and Jubilant Radiopharma maintain positions in diagnostic radiopharmaceuticals through PET and SPECT product portfolios that support oncology, cardiac, and other imaging applications.

In parallel, Novartis, Bayer AG, Telix Pharmaceuticals, and Sirtex Medical are strengthening their positions in therapeutic radiopharmaceuticals through radioligand therapy and targeted radionuclide treatment products. Eckert & Ziegler, AstraZeneca/Fusion Pharmaceuticals, Boston Scientific, and Actinium Pharmaceuticals further intensify competition through therapeutic product development, isotope capabilities, and radiopharmaceutical manufacturing. Overall, competition varies across product type, radionuclide, clinical indication, geographic presence, manufacturing capacity, and distribution networks.

Key Radiopharmaceutical Companies

The following key companies have been profiled for this study on the radiopharmaceuticals market.

• Lantheus

• Curium

• GE HealthCare

• Jubilant Radiopharma

• Blue Earth Diagnostics (Bracco)

• NCM USA

• Novartis (Advanced Accelerator Applications / Endocyte)

• Bayer AG

• Telix Pharmaceuticals

• Eckert & Ziegler

• Sirtex Medical

• Boston Scientific

• AstraZeneca / Fusion Pharmaceuticals

• Actinium Pharmaceuticals

Recent Developments

• In July 2026, Telix Pharmaceuticals dosed the first patient in the Phase III LUTEON trial evaluating TLX250-Tx, a lutetium-177-based radiopharmaceutical therapy for relapsed or recurrent clear cell renal cell carcinoma.

• In March 2025, Actinium Pharmaceuticals entered into a supply agreement with Eckert & Ziegler for Actinium-225 to support the development of Actimab-A and other radiopharmaceutical candidates in clinical trials.

• In March 2025, GE HealthCare completed the acquisition of Sumitomo Chemical’s remaining 50% stake in Nihon Medi-Physics (NMP), giving GE HealthCare full ownership of the Japanese radiopharmaceutical company.

Global Radiopharmaceutical Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2040. For this study, Grand View Research has segmented the global radiopharmaceuticals market report based on product, application, end use, and region:

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Billion, 2021 - 2040)

  • Diagnostic Radiopharmaceuticals

    • PET Radiopharmaceuticals

      • F-18 FDG Radiopharmaceuticals

      • Ga-68-based Radiopharmaceuticals

      • F-18 PSMA-based Radiopharmaceuticals

      • F-18 NaF Radiopharmaceuticals

      • F-18 Fluciclovine Radiopharmaceuticals

      • Rb-82-based Radiopharmaceuticals

      • N-13 Ammonia Radiopharmaceuticals

      • Others

    • SPECT Radiopharmaceuticals

      • Tc-99m-based Radiopharmaceuticals

      • I-123-based Radiopharmaceuticals

      • In-111-based Radiopharmaceuticals

      • Tl-201-based Radiopharmaceuticals

      • Others

  • Therapeutic Radiopharmaceuticals

    • Beta Emitters

      • Lu-177-based Radiopharmaceuticals

      • I-131-based Radiopharmaceuticals

      • Y-90-based Radiopharmaceuticals

      • Others

    • Alpha Emitters

      • Ra-223-based Radiopharmaceuticals

      • Ac-225-based Radiopharmaceuticals

• Application Outlook (Revenue, USD Billion, 2021 - 2040)

  • Diagnostic Radiopharmaceuticals

    • Oncology Imaging

    • Cardiac Imaging

    • Neurology Imaging

    • Endocrine Imaging

    • Renal Imaging

    • Infection & Inflammation Imaging

    • Others

  • Therapeutic Radiopharmaceuticals

    • Prostate Cancer

    • Neuroendocrine Tumors

    • Thyroid Disorders

    • Bone Metastases

    • Liver Cancer

    • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2040)

  • Hospitals

  • Diagnostic Imaging Centers

  • Ambulatory Surgery Centers

  • Specialty Clinics & Cath Labs

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Billion, 2021 - 2040)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The radiopharmaceutical market was estimated using a commodity flow and revenue-based modeling approach. The study began by identifying key manufacturers, radiopharmaceutical products, radionuclide suppliers, and major production facilities across diagnostic and therapeutic applications. Product-level analysis covered PET radiopharmaceuticals, SPECT radiopharmaceuticals, beta emitters, and alpha emitters, with further assessment of key isotopes such as F-18, Ga-68, Tc-99m, Lu-177, I-131, Y-90, Ra-223, and Ac-225. Diagnostic market estimates were developed using procedure volumes, tracer doses, product availability, and average selling prices, while therapeutic estimates considered treated patient volumes, dose requirements, treatment cycles, and product pricing. Manufacturer revenues, product sales, isotope production capacity, radiopharmacy supply, and treatment-center capacity were assessed to validate market estimates. Country-level revenues were aggregated to regional and global markets. Estimates were cross-checked using company disclosures, regulatory databases, clinical literature, procedure data, public pricing information, primary interviews, and data triangulation.

Estimation Model

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations